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Abstract
Background: Sphingolipids are key molecules regulating many essential functions in eukaryotic cells and
ceramide plays a central role in sphingolipid metabolism. A sphingolipid metabolism occurs in the
intraerythrocytic stages of Plasmodium falciparum and is associated with essential biological processes. It
constitutes an attractive and potential target for the development of new antimalarial drugs.
Methods: The anti-Plasmodium activity of a series of ceramide analogs containing different linkages (amide,
methylene or thiourea linkages) between the fatty acid part of ceramide and the sphingoid core was
investigated in culture and compared to the sphingolipid analog PPMP (d,1-threo-1-phenyl-2-
palmitoylamino-3-morpholino-1-propanol). This analog is known to inhibit the parasite sphingomyelin
synthase activity and block parasite development by preventing the formation of the tubovesicular
network that extends from the parasitophorous vacuole to the red cell membrane and delivers essential
extracellular nutrients to the parasite.
Results: Analogs containing methylene linkage showed a considerably higher anti-Plasmodium activity (IC50
in the low nanomolar range) than PPMP and their counterparts with a natural amide linkage (IC50 in the
micromolar range). The methylene analogs blocked irreversibly P. falciparum development leading to
parasite eradication in contrast to PPMP whose effect is cytostatic. A high sensitivity of action towards the
parasite was observed when compared to their effect on the human MRC-5 cell growth. The toxicity
towards parasites did not correlate with the inhibition by methylene analogs of the parasite sphingomyelin
synthase activity and the tubovesicular network formation, indicating that this enzyme is not their primary
target.
Conclusions: It has been shown that ceramide analogs were potent inhibitors of P. falciparum growth in
culture. Interestingly, the nature of the linkage between the fatty acid part and the sphingoid core
considerably influences the antiplasmodial activity and the selectivity of analogs when compared to their
cytotoxicity on mammalian cells. By comparison with their inhibitory effect on cancer cell growth, the
ceramide analogs might inhibit P. falciparum growth through modulation of the endogenous ceramide level.
Published: 10 December 2004
Malaria Journal 2004, 3:49 doi:10.1186/1475-2875-3-49
Received: 30 October 2004
Accepted: 10 December 2004
This article is available from: http://www.malariajournal.com/content/3/1/49
© 2004 Labaied et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
Page 2 of 10
(page number not for citation purposes)
Background
Sphingolipids are essential components of eukaryotic cell
membranes, predominantly found in the outer leaflet.
Sphingosine and ceramide (Figure 1) are the two simplest
molecules structurally, which belong to the sphingolipid
family. Sphingosine represents the sphingoid backbone,
and ceramide has a fatty acid linked in a amide bond to
sphingosine. Sphingolipid species have two types of func-
tional groups linked to the 1-position, i.e. sphingomyelin
(SPM) (Figure 1) having a phosphorylcholine group, and
a variety of glycolipids having either glucose, galactose,
galactosyl-sulfate or oligo-glycosides linked to the sphin-
gosine moiety of ceramide.
Until recently, sphingolipids were primarily considered to
be structural components of membranes. However, data
accumulated during the last decade have expanded the
view of their biological functions. They are now also con-
sidered to be key molecules which regulate many func-
tions essential to eukaryotic cells [1-5]. They are involved,
for example, in the regulation of membrane fluidity and
are part of discrete membrane microdomains or rafts
implicated in signalling and trafficking in cells [4,6-8].
Interest in sphingolipids was strengthened by an increas-
ing body of evidence demonstrating their role as second-
ary messengers for intracellular signal transduction
pathways that regulate many cellular processes. For exam-
ple, ceramide accumulates in response to several different
inducers such as cytokines, cytotoxic agents or to stressful
conditions, which lead to cell cycle arrest or to apoptosis
[9]. Sphingosine is a protein kinase C inhibitor [10] that
inhibits growth or stimulates proliferation, depending
upon the cell type [11,12].
Ceramide plays a central role in sphingolipid metabolism
[13]. It can be converted into SPM through transfer of the
choline phosphate group from phosphatidylcholine or
serves as a precursor for complex sphingolipids (cerebro-
sides which possess sugar residues and gangliosides which
contain sialic acid residues in addition to the carbohy-
drate units).
Moreover, ceramide can be phosphorylated by a distinct
kinase and can also be produced by enzymatic hydrolysis
of complex sphingolipids. In turn, ceramide can be hydro-
lyzed to sphingosine and fatty acid by ceramidases.
In contrast to yeast and mammalian cells, the current
understanding of sphingolipid metabolism and the bio-
logical role of sphingolipids in the development of Plas-
modium falciparum, the causative agent of malaria, is still
limited. Gerold et al. [14] provided evidence that de-novo
synthesis of sphingolipids occurs in the intraerythrocytic
stages of the human malaria parasite P. falciparum and can
be inhibited by the well established inhibitors of de-novo
ceramide biosynthesis, fumonisin B1, cyclo-serine and
myriocin [15,16]. However, these compounds are weak
inhibitors of parasite growth. Evidence was provided that
another pathway for the synthesis of glycosylated sphin-
golipids exists in P. falciparum [14,17]. The importance of
sphingolipid metabolism for parasite development was
demonstrated by Haldar's work showing that: (i) The par-
asite contains two distinct forms of SPM synthase, one
sensitive to sphingolipid analogs, d,1-threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP) or
d,1-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-
propanol (PPMP) (Figure 1), known to inhibit the synthe-
sis of glucosylceramide in mammalian cells [18], and the
second insensitive to them [19]; (ii) These analogs
blocked the parasite proliferation in culture by preventing
the formation of the tubovesicular network (TVN) that
extends from the parasitophorous vacuole to the red cell
membrane and delivers essential extracellular nutrients to
the parasite [20-22]. Neutral magnesium-dependent
sphingomyelinase activity was also identified in P. falci-
parum  [23-25], indicating that a sphingomyelin cycle
(ceramide-SPM conversion) exists in Plasmodium.
Recently, an increase in the intracellular ceramide content
and an activation of parasite sphingomyelinase(s) were
found to be associated with the parasite death process as
induced by artemisinine and mefloquine [26].
structures of sphingolipids and analogs Figure 1
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Given the importance of sphingolipids in many cellular
functions and the central role of ceramide in sphingolipid
metabolism, the anti-Plasmodium activity of non-natural
analogs of ceramides was investigated on the intraerythro-
cytic development of P. falciparum. Interestingly, a series
of analogs containing a methylene (CH2-NH) linkage
between the fatty acid and the sphingoid-analog core
showed considerably higher anti-Plasmodium activity than
their counterparts with a natural amide (CO-NH) linkage
or than PPMP. The methylene analogs irreversibly
blocked parasite development in contrast to PPMP whose
effect is cytostatic. Their efficiency in inhibiting parasite
growth did not correlate with their potential to inhibit
parasite SPM synthase activity, indicating that SPM syn-
thase is not their primary target. Possible mechanisms of
action are discussed.
Methods
Materials
D,1-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-
propanol-HCl (D,1-threo-PPMP) was purchased from
Matreya (Pleasant Gap, PA). 6-((N- (7-nitrobenz-2-oxa-1,
3-diazol-4-yl) amino) hexanoyl sphingosine (NBD-C6-
ceramide) and N- (4,4-difluoro-5, 7-dimethyl-4-bora-3a,
4a-diaza-s-indacene-3-pentanoyl) sphingosyl phospho-
choline (BODIPY-FL-C5-ceramide) were obtained from
Molecular Probes, Inc. (Eugene, OR). The compounds of
Figure 3 and Figure 4 were synthesized according to the
procedure described by Dagan et al [27], using specific
starting materials for each analog. The compounds of Fig-
ure 2 were synthesized by linking specific fatty acids to the
amino group of substituted 1,3-dihydroxy-2-aminophe-
Anti-P. falciparum activity of ceramide analogs having an  amide linkage (series A) Figure 2
Anti-P. falciparum activity of ceramide analogs having an 
amide linkage (series A).
CH2OH
NH
OH
x
Y
1
2
3
Compound 
X Y  CI50 (µM)  CI90 (µM) 
AD2648 (-)  CH3-(CH2)10-CO-NH- H-  4.9
a 9.6
a 
AD2590 (-)  NO2- CH3-CO- >100
a - 
AD2583 (-)  NO2- CH3-(CH2)2-CO- 26.8
a  67.4
a 
AD2549 (+)  NO2- CH3-(CH2)2-CO- >100
a - 
AD2607 (-)  CH3-(CH2)2-CO-NH- CH3-(CH2)2-CO- >  100
a - 
AD2606 (-)  COOH-(CH2)2-CO-NH- CH3-(CH2)2-CO- >100
a - 
AD2603 (-)  CH3-(CH2)6-CO-NH- CH3-(CH2)2-CO- 70.1
a  >100
a 
AD2604 (-)  CH3-(CH2)10-CO-NH- CH3-(CH2)2-CO- 70.0
a >100
a 
AD2605 (-)  CH3-(CH2)14-CO-NH- CH3-(CH2)2-CO- >100
a - 
AD2589 (-)  NO2- OH-(CH2)3-CO- >100
a - 
AD2494 (-)  NO2- CH3-(CH2)6-CO- 13.1
a 70
a 
AD2550 (+)  NO2- CH3-(CH2)6-CO- 64.1
a  >100
a
AD2552 (-)  NO2- CH3-(CH2)10-CO- 16.5  + 6.5
b 36.3  + 16.1
b 
AD2557 (-)  NO2- CH3-(CH2)12-CO- 17.2  + 5.5
b 37.8  + 15.3
b
AD2560 (+)  NO2- CH3-(CH2)12-CO- 18.7  + 6.5
b  36 + 18.2
b 
AD2495 (-)  NO2- CH3-(CH2)14-CO- 10.8  + 2.3
b  20.3 + 1.4
b 
AD2623 (-)  NH2- CH3-(CH2)14-CO- 40.4
a  81.3
a 
AD2558 (-)  NO2- CH3-(CH2)16-CO- 34.3
a  >50
a 
Number of experiments: a, n = 2; b, n = 3; (-): D-threo. (+):L-threo.
Anti-P. falciparum activity of ceramide analogs having a meth- ylene or a thiourea linkage (series B) Figure 3
Anti-P. falciparum activity of ceramide analogs having a meth-
ylene or a thiourea linkage (series B).
Anti-P. falciparum activity of selected derivatives Figure 4
Anti-P. falciparum activity of selected derivatives
CH2OH
NH
OH
x
Y
1
2
3
Compounds
X Y  CI50 (nM)  CI90 (nM)
AD-2212  (-)  NO2- CH3-CH2- >33000
b - 
AD-2493  (-)  NO2- CH3-(CH2)3- 780  + 70
b  5100 + 150
b 
AD-2617 (-)  NO2- CH3-(CH2)11- 17.1  + 5.3
b  304 + 7
b 
AD-2646 (-)  NO2- CH3-(CH2)13- 30.8  + 4.6
b  57.7 + 3.2
b 
AD-2645 (+)  NO2- CH3-(CH2)13- 37.9  + 2.1
b  104 + 1
b 
AD-2672 (-)  NH2- CH3-(CH2)13- 1700  + 200
b  2600 + 650
b 
AD-2678 (-)  CH3-CO-NH- CH3-(CH2)13- 5800
a  10600
a 
AD-2677 (-)  CH3-CH2-NH- CH3-(CH2)13- 1480
a  2700
a 
AD-2680 (-)  CH3-(CH2)4-CO-NH- CH3-(CH2)13- 3300
a 5500
a 
AD-2619 (-)  NO2- CH3-(CH2)15- 42.8  + 8.5
b 73  + 5
b 
AD-2554 (-)  NO2- CH3-(CH2)19- >200000
a - 
AD-2664 (-)  CH3-(CH2)3-NH- CH3-(CH2)3- 1300  + 200
b 2400  + 700
b 
AD-2651 (-)  CH3-(CH2)5-NH- CH3-(CH2)5- 85.7  + 23.2
b 135  + 19
b 
AD-2670 (-)  CH3-(CH2)7-NH- CH3-(CH2)7- 33.7  + 3.7
b 69  +3
b 
AD-2653 (-)  CH3-(CH2)11-NH- CH3-(CH2)11- 3250
a  5500
a 
AD-2215 (-)  NO2- CH3-CH2-NH-CS- >50000
a - 
AD-2216 (-)  NO2- CH3-(CH2)3-NH-CS- 1130  + 240
b 13900  + 7100
b 
AD-2217 (-)  NO2- C(CH3)3-NH-CS- 574  + 50
b 958  + 13
b 
Number of experiments: a, n = 2; b, n = 3. (-): D-threo. (+):L-threo.
CH2
NH
Y
x
1
2
3 Z
(CH3)13 H3C
Compounds  X Y Z  IC50 (nM)
AD-2646 (-)  NO2- OH- OH-  30.8  + 4.6
AD-2730 (-)  H- OH-  OH-  18.9  + 1.7 
AD-2729 (-)  H- H-  OH-  257.9  + 10.7 
AD-2724 (-)  H- OH- H-  33.4  + 3.1 
IC50 values are the mean + standard deviations of three independent experiments. (-): D-threo.Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
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nyl derivatives. The full description of the synthesis of
each specific analog will be described in a separate
publication.
P. falciparum culture and synchronization
P. falciparum strains (FcB1/Colombia, K1/Thailand, F32/
Tanzania, W2/Indochina) were maintained in continuous
culture on human erythrocytes in RPMI medium contain-
ing 7% (v/v) heat-inactivated human serum under an
atmosphere of 3% CO2, 6% O2, 91% N2, at 37°C, as
described by Trager and Jensen [28]. Parasite synchroniza-
tion was performed successively by treatment with 5% (w/
v) sorbitol and by concentration in gelatin solution as pre-
viously described [29].
Anti-Plasmodium activity
Drug susceptibility assays were performed using a modifi-
cation of the semi automated microdilution technique of
Desjardins et al. [30]. Stock solutions of test compounds
were prepared in DMSO. Drug solutions were serially
diluted twofold with 100 µl culture medium in 96-well
plates. Asynchronous parasite cultures (100 µl, 1 % para-
sitemia and 1 % final hematocrite) were added to each
well and incubated for 24 hours at 37°C prior to the addi-
tion of 0.5 µCi of [3H] hypoxanthine (Amersham, France,
1 to 5 Ci.mmol/ml) per well. After a further incubation of
24 hour, plates were frozen and thawed. Cell lysates were
then collected onto glass-filter papers and counted in a
liquid scintillation spectrometer. The growth inhibition
for each drug concentration was determined by compari-
son of the radioactivity incorporated in the treated culture
with that in the control culture (having the same final %
of DMSO) maintained on the same plate. The concentra-
tion causing 50% growth inhibition (IC50) and 90%
growth (IC90) were obtained from the drug concentration-
response curve and the results were expressed as the
means ± the standard deviations determined from several
independent experiments. The DMSO concentration
never exceeded 0.1% (v/v) and did not inhibit the parasite
growth.
Cytotoxicity test upon human embryonic cells
A human diploid embryonic lung cell line (MRC-5, Bio-
Whittaker 72211D) was used to assess the cytotoxic effects
towards eukaryotic host cells. MRC-5 cells were seeded at
5,000 cells per well in 100 µl. After 24 hours, the cells were
washed and two-fold dilutions of the drug were added in
200 µl standard culture medium (RPMI medium + 5%
fetal calf serum) and maintained for five days under 5%
CO2 atmosphere. The final DMSO concentration in the
culture remained below 0.1%. Untreated cultures were
included as controls. The cytotoxicity was determined
using the colorimetric MTT assay according to the manu-
facturer's recommendations (Cell proliferation kit I,
Roche Applied Science, France) and scored as a percentage
of reduction in absorption at 540 nm of treated cultures
versus untreated control cultures. IC50  values were
obtained from the drug concentration-response curve.
The results were expressed as the mean ± the standard
deviations determined from several independent experi-
ments. The index of selectivity was defined as the ratio of
the IC50 value on MRC-5 to that of P. falciparum.
Parasite stage-specific inhibitory effects and reversibility
Synchronized cultures (1–2% parasitemia) at the ring
stage (0–10 hours old parasites), the trophozoite stage
(25–35 hours old parasites) and the schizonte stage (40–
48 hours old parasites) were maintained in the presence
of drug concentrations in the vicinity of IC50 values. Aliq-
uots were removed at the indicated times, washed three
times with culture medium and maintained in culture in
the absence or in the presence of a given drug. Parasite
morphology was determined on Giemsa-stained smears
defined according to the following criteria: the ring stage,
when parasites exhibited a peripheral cytoplasm stained
by Giemsa and a unstained intraparasitic vacuole; the tro-
phozoite stage, when parasites showed a fully stained
cytoplasm, haemozoin crystals and one nucleus; the
schizont stage, when parasites presented several distinc-
tive nuclei. Parasitaemias were determined by counting
3,000 cells for each sample. Controls consisted of para-
sites incubated with DMSO instead of drugs processed in
the same way.
Sphingomyelin synthase activity assays
SPM synthase activity was measured as described by
Haldar et al. [31]. Briefly, assays were performed on P. fal-
ciparum cultures at the trophozoite stage (20–30 h old par-
asites). 400 µl of culture (1 × 108  parasites) were
incubated for 60 min at 37°C with 10 µM NBD-C6-cera-
mide and 0 to 500 µM PPMP or AD2646. Cells were then
lysed by freezing and thawing of the culture. Lipids were
extracted by a modification of the method of Bligh and
Dyer [32]. To each sample, three volumes of a CH3OH/
CHCl3 mixture (1:2, v:v) were added and the mixture vor-
texed for one min. Organic and aqueous phases were sep-
arated by centrifugation (12,000 × g, five min) and the
organic phase was dried. Lipids were dissolved in 15 µl
ethanol and analysed by thin layer chromatography on
HPTLC plates (Silica gel 60 F254, Merck, Darmstadt, Ger-
many) in CH3OH/CH3Cl3/NH4OH (75:25:4, v:v:v). For
qualitative analyses, the fluorescent lipids were detected
under UV and for quantitative analyses, the fluorescent
lipid spots were scraped, eluted in one ml methanol and
quantified at an excitation of 470 nm and an emission of
530 nm in a spectrofluorometer. The percentage of SPM
synthase activity for each drug concentration was deter-
mined by comparison of the fluorescence quantified in
the analog-treated culture with that in the control culture
(without drug).Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
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Labelling of infected red blood cells and fluorescence 
microscopy
Infected erythrocytes treated with or without ceramide
analogs were incubated for 30 min, at 37°C, in culture
medium containing 10 µM BODIPY-FL-C5-ceramide,
washed three times with culture medium without serum
and fixed overnight, at 4°C, in 3.7% formaldehyde/
0.05% glutaraldehyde. Cells were mounted on poly-L-
lysine coated slides and viewed using a Nikon Eclipse TE
300 DV inverted microscope with an 100X oil objective
mounted on a piezzo electric device using appropriate flu-
orescence emission filters. Image acquisition (z-series)
was performed with a back illuminated cooled detector
(CCD EEV: NTE/CCD-1024-EB, Roper Scientific, France)
using a 0.2 µm step. Data acquisition and image deconvo-
lution process were performed with Metamorph software
(Universal Imaging Corporation, Roper Scientific,
France). The images presented correspond to the maxi-
mum intensity projection of the deconvoluted z-series.
Results and Discussion
Anti-Plasmodium activity of non-natural ceramide analogs
Non-natural analogs of ceramides were synthesized com-
prising two functional groups [27] : 1) A phenyl group
substituted on carbon 3 of a sphingoid-like backbone;
with the phenyl group replacing the sphingosine acyl
chain [33,34] to which were linked nitro or amine groups,
or carbon chains of varying lengths; and 2) a fatty acid
with an amide (CO-NH) linkage (series A, Figure 2), a
methylene (CH2-NH) or a thiourea (CS-NH) linkages
(series B, Figure 3) on carbon 2. Analogs in which the
alkyl group replaces the amide were investigated because
the carbonyl group of ceramide was shown not to be nec-
essary for triggering apoptosis in mammalian cells. In fact,
replacement of the carbonyl group of ceramide by a meth-
ylene group substantially reduced the time required for
cell death [35]. Only D/L-threo enantiomers were investi-
gated on P. falciparum since reports demonstrated that D/
L-erythro enantiomers of ceramide analogs were less effi-
cient in inhibiting glucosylceramide synthase in mamma-
lian cells [18] and did not inhibit SPM synthase activity in
P. falciparum [19].
Figure 2 and Figure 3 show the IC50 values obtained for
the different compounds on the development of the chlo-
roquine-resistant strain FcB1 of P. falciparum in culture
(IC50 value for chloroquine = 115 ± 25 nM, n = 3). Inter-
estingly, the nature of the linkage considerably influences
the anti-Plasmodium activity. Analogs with amide linkage
were found to inhibit parasite growth with IC50 values in
the micromolar range (Figure 2). Best IC50 values were
similar to that obtained with the ceramide-related
compound PPMP (IC50 = 9.0 ± 1.7 µM, n = 3). However,
this IC50 value for PPMP differed from the previously
reported value (IC50 = 0.85 µM) [19]. The discrepancy
may be due to drug susceptibility assay conditions which
were performed on synchronized cultures at the ring stage
for Lauer et al. [19] and on asynchronous cultures in the
present study. Analogs with methylene linkages were
more efficient than the amide analogs in killing parasites
with IC50 values in the nanomolar range (Figure 3).
For the D-threo nitro phenyl analogs of series A, no partic-
ular increase of the inhibitory activity was observed with
the increase of the N-acyl chain length (IC50  values
ranging from 10.8 to 40.4 µM, Figure 2). For the series B,
best activities were observed for N-alkyl chain length of
12–16 carbons (IC50 values ranging from 17 to 42 nM for
the series B, Figure 3). In both series, substitution of the
nitrophenyl group by an aminophenyl group instead of
nitro group decreased the anti-Plasmodium activity signifi-
cantly (compare compounds AD2495 and AD2623 of
series A, Figure 2; and compounds AD2646 and AD2672
of series B, Figure 3).
Increase of the analog hydrophobicity by substitution of
the nitro group of the phenyl ring by alkyl chains seems to
decrease the anti-Plasmodium  activity of compounds of
both series (compare compounds AD2583 and AD2603-
7, Figure 2 and compounds AD2646 and AD2677-78-80,
Figure 3). Surprisingly, in the B series, the anti-Plasmodium
activity was restored in compounds with symmetrical
alkyl chains of 6–8 carbon length (compounds AD2651
and AD2670, Figure 3). No systematic difference in anti-
Plasmodium activity was observed between D-threo and L-
threo enantiomer of a same analogue: e.g. the enantiomers
AD2646 and AD2645 of the B series showed similar activ-
ity (Figure 3). It can also be noted that ceramide analogs
containing a thiourea linkage also showed a significant
anti-Plasmodium activity (Figure 3, compounds AD2215-
17) with, however, a less pronounced inhibitory effect
than analogs with a methylene linkage.
Inhibition of parasite growth by the methylene analog
AD2646 was observed having similar IC50 values on the P.
falciparum strains K1 (IC50 = 45 nM), F32 (IC50 = 21 nM)
and W2 (IC50 = 28 nM), suggesting that the drug is not
restricted to a specific strain and acts through a conserved
mechanism in malarial parasites. Furthermore, analysis of
drug combination with antimalarial drugs showed that
AD2646 has a non-synergistic and non-antagonistic effect
with CQ on the CQ-resistant strain K1, and with meflo-
quine and with artemether on the FcB1 strain (data not
shown). Compound AD2646 (Figure 1) was selected to
further investigate the biological effects of methylene ana-
logs on parasite development.
Structure-activity relationship around AD2646 showed
that the presence of a nitro group linked to the phenyl is
not essential for anti-Plasmodium  activity (Figure 4,Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
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compare IC50  values of compounds AD2646 and
AD2730) nor hydroxylation on carbon 1 (compare com-
pounds AD2730 and AD2724). In contrast, hydroxylation
of carbon 3 is important for anti-Plasmodium activity since
removal of the hydroxyl group reduced the activity 13.5
times (compare compounds AD2730 and AD2729).
Cytotoxicity on human cells MRC-5 of ceramide analogs in 
methylene linkage
The cytotoxicity of methylene analogs upon human MRC-
5 cells (diploid embryonic lung cell line) was evaluated
(Table 1). Derivatives tested showed IC50 values in the
micromolar range, from 5 to 8 µM (except for AD2619),
which are similar to the IC50 value of PPMP. No major dif-
ference of toxicity was observed between D- and L-threo
enantiomers (compare AD2646 and AD2645). In contrast
to what was observed for P. falciparum, hydroxylation of
the sphingosine carbon 3 does not seem important for
cytotoxicity since similar IC50 values were measured for
AD2646 and AD2729, suggesting different mechanism(s)
of action for AD2646 on MRC-5 cells and P. falciparum.
AD2646 and 4 derivatives show high selectivity for P. fal-
ciparum as illustrated by the high index of selectivity of
these compounds ranging from 160 to 624. The index of
selectivity was defined as the ratio of the IC50 value on
MRC-5 cells to that on P. falciparum. It can be noted that
no selectivity was observed for PPMP. A similar range of
growth inhibition was measured on P. falciparum (Figure
2) and HL-60 cells [36] with ceramide analogs in amide
linkage supporting a weak selectivity of these analogs for
P. falciparum.
It must be emphasized that the amide linkage of ceramide
analogs is not required for activating apoptosis in cancer
cells [35]. An increase of cytotoxicity of ceramide analogs
in methylene linkage compared to their counterparts in
amide linkage was also observed on the human histolytic
lymphoma U937 [35] and the human leukaemia HL-60
cells [27] however, with higher IC50  values than that
observed with P. falciparum.
Stage-specific inhibitory effects of AD2646 and 
reversibility
To investigate the cytostatic or cytotoxic effects of AD2646
on the parasite development, cultures at the ring stage (0–
10 hours), the trophozoite stage (25–35 hours) and the
schizonte stage (40–48 hours) were incubated with 30,
100 or 250 nM of AD2646 for 24.5 hours for the ring
stage, for 11 hours for the trophozoite stage, and for 14
hours for the schizonte stage. Aliquots were then taken,
washed and incubated in the absence or the presence of
drug for a further 13 hours to 24 hours depending upon
the parasite stage tested (see Figure 5). Parasitaemia and
parasite stages were determined on Giemsa-stained
smears at time of aliquot removal and after the subse-
quent incubation.
Development of the ring stage was slightly affected by a
continuous incubation with 30 nM AD2646. In contrast,
when incubated with 100 and 250 nM, parasite growth
was irreversibly blocked at the young trophozoite stage
and the parasite degenerated. Drug removal after 24 hours
of incubation did not allow a recovery of parasite growth
(Figure 5A). The trophozoite stages were more sensitive to
AD2646 since a continuous incubation with 30 nM com-
pletely blocked development. Parasites did not enter into
division and then degenerated. Only a partial recovery of
parasite growth was observed when drug was removed
after 11 hours of incubation. A more marked effect was
observed with 100 nM AD2646 with degenerated para-
sites already observed after only 11 hours. No recovery of
parasite growth was then observed after drug removal
(Figure 5B). The schizont stage appeared less sensitive
than the trophozoite stage since a slight effect was only
observed on the parasite development with 30 nM
AD2646. However, parasite growth was irreversibly
blocked by an incubation with 100 nM AD2646 and par-
asites degenerated (Figure 5C). Similar results were
observed for the methylene analogs AD2651 and
AD2670, the trophozoite stage being the most sensitive
with a complete inhibition of parasite development for
250 nM (data not shown).
It can be noted that, in contrast to methylene analogs,
addition of PPMP to parasite culture led to a preferential
and reversible arrest of parasite development at the ring
stage. The schizont stage (>30 hours old parasites) was
insensitive to this concentration of drugs [14,19]. A cyto-
static effect of PPMP on the ring-stage was effectively
observed : rings blocked by a 24 hours incubation with 5
µM PPMP recovered to a normal growth after drug
removal (data not shown). Blockage of parasite
development was associated with the inhibition of a
Table 1: Cytotoxicity of methylene analogs and PPMP on human 
MRC-5 cells
Compounds IC50 (µM) IC90 (µM) Index of selectivity
AD2646 (-) 4.9 7.5 160
AD2645 (+) 6.1 10.3 161
AD2672 (-) 3.7 5.9 2
AD2730 (-) 6.1 9.9 322
AD2729 (-) 5.8 9.8 22
AD2619 (-) 26.7 42.3 624
PPMP 7.5 12.4 0.8
IC50 and IC90 values are the mean of three independent experiments. 
The S.E. were within 10% of the mean. (-): D-threo, (+): L-threo. Index 
of selectivity is defined by the ratio of the IC50 value on MRC-5 cells to 
that on P. falciparum.Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
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sensitive SPM synthase and TVN formation that delivers
extracellular nutrients to the parasite [20-22].
Inhibition of sphingomyelin synthase activity and 
tubovesicular network formation of P. falciparum by 
compound AD2646
Figure 6 reproduces the inhibitory effects of PPMP and the
methylene analogue AD2646 on the SM synthesis activity
of young trophozoite (20–30 hours)-infected erythrocytes
maintained in culture. As previously reported [19], no
SPM synthase activity was measured in non-infected red
blood cells and a biphasic inhibition curve was observed
with PPMP in infected erythrocytes. Two pools of SPM
synthase activity are present in parasites with respect to
their inhibition by the ceramide analogue, one very sensi-
tive to the drug and the second only inhibited by high
concentrations of drug. The biphasic inhibition curve that
superimposes on the PPMP inhibition curve was also
recorded for AD2646 indicating that PPMP and AD2646
inhibit the SPM synthase activity of infected-red blood
cells in a similar way.
In contrast, PPMP and AD2646 have completely different
effects on the TVN formation for drug concentrations that
P. falciparum stage sensitivity to AD2646 Figure 5
P. falciparum stage sensitivity to AD2646. Parasites at 
the ring (A), trophozoite (B) and schizonte (C) stages were 
maintained in the presence of 30 nM (square) or 100 nM (tri-
angle) AD2646 for 24 h30, 11 h and 14 h, respectively. Aliq-
uots were then taken, washed and maintained in culture in 
the absence (open symbol) or in the presence (full symbol) of 
the same concentration of analog. Controls were cultures 
maintained in the absence of drug (full circle) and processed 
as the treated cultures. Parasitemia and parasite morphology 
were determined on Giemsa-stained smears at the indicated 
time. Each value is the mean of two independent 
experiments.
Inhibition of P. falciparum sphingomyelin synthase activity by  AD2646 and PPMP Figure 6
Inhibition of P. falciparum sphingomyelin synthase 
activity by AD2646 and PPMP. Trophozoite cultures 
(20–30 hours aged parasites) were incubated with 0–500 µM 
PPMP (full square) or AD2646 (open square) and 10 µM 
NBD-C6-ceramide for 60 min, at 37°C. SPM synthase activity 
was measured as described by Lauer et al. [19]. The percent-
age of SPM activity was determined by comparison of the 
activity measured in control cultures maintained without the 
analogs. Each value is the mean of triplicate experiments.Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
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block parasite growth. After 24 hours of incubation, ring
development was totally inhibited by 5 µM PPMP and no
TVN was observed as previously described [20] (Figure
7C). As in controls maintained without drug (Figure 7A),
TVN was distinctly observed after 24 hours of incubation
of rings with 60 nM AD2646 (Figure 7B). This concentra-
tion blocks irreversibly the parasite development indicat-
ing that AD2646 has no major effect on TVN formation.
These data do not support the hypothesis of parasite
growth inhibition due to an inhibition of the parasite
SPM synthase activity as was demonstrated for PPMP [19-
22] : 1) The anti-Plasmodium activity of AD2646 does not
correlate with its inhibitory activity on the SPM synthase.
Although AD2646 and PPMP showed similar inhibitory
activity on this enzymic activity in parasites in cultures,
AD2646 is about 300 times more efficient in inhibiting
parasite development than PPMP; 2) In contrast to PPMP
which inhibits the parasite development preferentially
and reversibly at the ring stage [19], AD2646 inhibited
parasite development preferentially and irreversibly at the
trophozoite stage (Figure 5); 3) Inhibition of the SPM syn-
thase activity by PPMP is associated with an inhibition of
the TVN formation [19-22]. This was not observed in the
presence of AD2646 (Figure 7).
What could be the mechanism(s) of action of ceramide 
analogs in methylene linkage on P. falciparum?
By their lipidic nature, these analogs might act through a
detergent effect that could lead to lysis or modification of
the integrity of infected-erythrocyte membranes. This
apparently is not the case. No significant lysis of normal
erythrocytes was observed after 48 hous of incubation
with concentrations of analogs up to 10 µM (data not
shown). Furthermore, no preferential lysis of infected-
erythrocytes was observed on Giemsa-stained smears of
infected cultures maintained 48 hours with 250 nM
AD2646, a concentration inhibiting parasite growth
totally.
Interestingly, the absence of a fatty acyl carbonyl group
(methylene linkage) in our ceramide analogs is a critical
factor for the efficacy of their antiplasmodial activity.
Sphingolipids preferentially interact with cholesterol in
membranes, especially in detergent-resistant microdo-
mains (DRMs or rafts). Rafts have been described in Plas-
modium  and are involved, at least, in the uptake of
erythrocyte raft proteins and maintenance of the parasito-
phorous vacuole containing the parasite, inside the eryth-
rocyte [37]. This interaction implies : 1) van der Waals
interactions between the saturated acyl chain and sphin-
goid moiety of sphingolipids and the rigid planar tetracy-
clic rings of cholesterol [38] and 2) hydrogen bonds
between the 3-β hydroxyl group of cholesterol and the
fatty acyl carbonyl group resulting from the amide linkage
with the sphingoid moiety [39]. The amide-linked fatty
acid function seems to have a profound stabilizing effect
on cholesterol-sphingolipid interactions [40]. It could be
hypothesized that in a membrane context, methylene ana-
logs might have a destabilizing effect on the cholesterol-
sphingolipid interactions and, in consequence,
modifications of membrane properties. Indeed, P. falci-
Effects of AD2646 and PPMP on the formation of the tubovesicular network of P. falciparum Figure 7
Effects of AD2646 and PPMP on the formation of the tubovesicular network of P. falciparum. Infected erythro-
cytes at the ring stage were incubated for 24 hours in presence of 60 nM AD2646 (B) or 5 µM PPMP (C). TVN formation in 
treated cells and untreated cells (A) was evaluated by membrane staining using BODIPY-Fl-C5-ceramide. Arrow: TVN. Bar: 5 
µm.Malaria Journal 2004, 3:49 http://www.malariajournal.com/content/3/1/49
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parum growth is characterized by a setting up of new per-
meabilities of the infected-erythrocyte membrane [41].
Although the biochemical nature of these new permeabil-
ities is still unknown, they have been characterized from
an electrophysiological point of view and involve a
malaria-induced anion channel [42,43]. The effect of cera-
mide analogs was investigated on the properties of this
channel. A 24 hours-incubation of infected-erythrocytes
with 250 nM AD2646 or 10 µM PPMP did not modulate
significantly the induced channel activity measured in the
whole-cell configuration of the patch-clamp technique (S.
Egee, unpublished data), suggesting that these ceramide
analogs do not inhibit parasite growth through modifica-
tions of infected-erythrocyte membrane permeabilities.
Ceramide is at the parting of different ways of sphingoli-
pid metabolism. Analogs have the potential to inhibit dif-
ferent ceramide-metabolizing enzymes and then might
have a pleiotropic effect. Ceramide analogs in amide link-
age were described as potent inhibitors of alkaline
ceramidase in HL60 human myeloid leukemic cells
[44,45]. Methylene analogs inhibit the biosynthesis of
SPM and glycosphingolipids in HL60 cells, and acid
ceramidase in vitro [10]. When applied to cancer cells,
such analogs induced an elevation of the endogenous
level of ceramide with the consequent effects of growth
suppression and cell death by apoptosis [44,45]. In con-
trast to what was observed for cancer cells [27], prelimi-
nary results suggest that the ceramide analog AD2646
induced non-apoptotic death of P. falciparum. Parasites
exposed to 1 µM AD2646 for up to 36 hours failed to
exhibit characteristic apoptosis, as determined by termi-
nal deoxynucleotidyl transferase DNA fragmentation
assay and DNA fragmentation using both gel electro-
phoresis and fluorescence microscopy methods, although
the nucleus appeared highly condensed (M. Dellinger,
unpublished data). Apoptosis in P. falciparum is still con-
troversial although some characteristics of apoptosis has
been described in Plasmodium [46]. Recently, an increase
in the intracellular ceramide content and an activation of
parasite sphingomyelinase(s) were found to be associated
with a non-apoptotic parasite death process as induced by
artemisinine and mefloquine [26]. The hypothesis that
AD2646 induced parasite death through modulation of
endogenous ceramide level, as observed for cancer cells, is
under investigation.
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